Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum.
AOMS3
DYRK1B
Diabetes
Metabolic syndrome
Monogenic, and Obesity
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
30 06 2021
30 06 2021
Historique:
received:
15
12
2020
accepted:
20
06
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
6
8
2021
Statut:
epublish
Résumé
We investigated pathogenic DYRK1B variants causative of abdominal obesity-metabolic syndrome 3 (AOMS3) in a group of patients originally diagnosed with type 2 diabetes. All DYRK1B exons were analyzed in a sample of 509 unrelated adults with type 2 diabetes and 459 controls, all belonging to the DMS1 SIGMA-cohort (ExAC). We performed in silico analysis on missense variants using Variant Effect Predictor software. To evaluate co-segregation, predicted pathogenic variants were genotyped in other family members. We performed molecular dynamics analysis for the co-segregating variants. After filtering, Mendelian genotypes were confirmed in two probands bearing two novel variants, p.Arg252His and p.Lys68Gln. Both variants co-segregated with the AOMS3 phenotype in classic dominant autosomal inheritance with full penetrance. In silico analysis revealed impairment of the DYRK1B protein function by both variants. For the first time, we describe age-dependent variable expressivity of this entity, with central obesity and insulin resistance apparent in childhood; morbid obesity, severe hypertriglyceridemia, and labile type 2 diabetes appearing before 40 years of age; and hypertension emerging in the fifth decade of life. We also report the two youngest individuals suffering from AOMS3. Monogenic forms of metabolic diseases could be misdiagnosed and should be suspected in families with several affected members and early-onset metabolic phenotypes that are difficult to control. Early diagnostic strategies and medical interventions, even before symptoms or complications appear, could be useful.
Sections du résumé
BACKGROUND
We investigated pathogenic DYRK1B variants causative of abdominal obesity-metabolic syndrome 3 (AOMS3) in a group of patients originally diagnosed with type 2 diabetes. All DYRK1B exons were analyzed in a sample of 509 unrelated adults with type 2 diabetes and 459 controls, all belonging to the DMS1 SIGMA-cohort (ExAC). We performed in silico analysis on missense variants using Variant Effect Predictor software. To evaluate co-segregation, predicted pathogenic variants were genotyped in other family members. We performed molecular dynamics analysis for the co-segregating variants.
RESULTS
After filtering, Mendelian genotypes were confirmed in two probands bearing two novel variants, p.Arg252His and p.Lys68Gln. Both variants co-segregated with the AOMS3 phenotype in classic dominant autosomal inheritance with full penetrance. In silico analysis revealed impairment of the DYRK1B protein function by both variants. For the first time, we describe age-dependent variable expressivity of this entity, with central obesity and insulin resistance apparent in childhood; morbid obesity, severe hypertriglyceridemia, and labile type 2 diabetes appearing before 40 years of age; and hypertension emerging in the fifth decade of life. We also report the two youngest individuals suffering from AOMS3.
CONCLUSIONS
Monogenic forms of metabolic diseases could be misdiagnosed and should be suspected in families with several affected members and early-onset metabolic phenotypes that are difficult to control. Early diagnostic strategies and medical interventions, even before symptoms or complications appear, could be useful.
Identifiants
pubmed: 34193236
doi: 10.1186/s13023-021-01924-z
pii: 10.1186/s13023-021-01924-z
pmc: PMC8247206
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
291Références
J Comput Chem. 2006 Nov 15;27(14):1765-8
pubmed: 16917862
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Int J Obes (Lond). 2020 Apr;44(4):830-841
pubmed: 30926952
Sci Rep. 2017 Jul 25;7(1):6420
pubmed: 28743892
J Mol Graph Model. 2002 Aug;21(1):47-9
pubmed: 12413030
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
N Engl J Med. 2014 May 15;370(20):1909-1919
pubmed: 24827035
Metab Syndr Relat Disord. 2018 Oct;16(8):395-405
pubmed: 30063173
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
Salud Publica Mex. 2010;52 Suppl 1:S11-8
pubmed: 20585723
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Biol Chem. 2009 Jan 2;284(1):478-485
pubmed: 19001369
Methods Mol Biol. 2018;1706:3-16
pubmed: 29423790
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
JCI Insight. 2020 Jan 16;5(1):
pubmed: 31821176
Nature. 2014 Feb 6;506(7486):97-101
pubmed: 24390345
Biochem Biophys Res Commun. 2003 Jan 17;300(3):764-9
pubmed: 12507516
N Engl J Med. 2014 Aug 21;371(8):784-5
pubmed: 25140973
Hormones (Athens). 2018 Sep;17(3):299-313
pubmed: 30171523
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):365-367
pubmed: 28587579